EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Inclusion Criteria: * Histologically-confirmed intracranial glioblastoma or gliosarcoma (World Health Organization \[WHO\] grade IV) with evidence of clinical and radiographic (computed tomography \[CT\] or MRI brain) tumor progression (need not be biopsy proven) * Patients who have undergone prior resection, radiation therapy, and/or chemotherapy (except bevacizumab) * Karnofsky performance score \>= 70 or Eastern Cooperative Oncology Group (ECOG) performance status = 0 or 1 * Patient agrees to undergo a baseline and a follow-up 11C-alpha-methyl-L-tryptophan (AMT)-PET scan during immunotherapy (IMT) * No serious medical or psychiatric illness which prevents informed consent or intensive treatment is allowed * Non pregnant: negative serum test for pregnancy, unless male, prior hysterectomy, tubal ligation, or postmenopausal; (Note: postmenopausal is defined as age \> 55 with amenorrhea for \> 1 year or age \< 55 years with amenorrhea for 2 years and follicle stimulating hormone (FSH) level within postmenopausal range of institutional parameters; patients requiring FSH level to determine menopausal status need not have this performed and may choose to proceed with serum pregnancy testing) * Required initial laboratory data (normal limits per treating institution; minor changes from the indicated laboratory guidelines will be allowed at the discretion of the treating team under special circumstances and reasons for the changes will be documented): * Granulocytes \>= 1,000/mm\^3 * Absolute lymphocyte count \>= 500/mm\^3 * Platelet count \>= 50,000/ul * Hemoglobin \>= 8 gm/dl * Blood urea nitrogen (BUN) =\< 1.5 times normal * Serum creatinine \< 1.8 mg/dl * Creatinine clearance \>= 50 ml/mm (can be calculated utilizing the Cockcroft \& Gault equation) * Bilirubin \< 1.5 times upper limit of normal * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 times upper limit of normal * Alkaline phosphatase \< 5 times upper limit of normal * Prothrombin time (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) \< 1.2 times upper limit of normal * Negative human immunodeficiency virus (HIV)-1/2 serology * Negative hepatitis B surface antigen * Negative hepatitis C serology * Left ventricular ejection fraction (LVEF) \>= 45% at rest (multi gated acquisition \[MUGA\] or echocardiogram \[ECHO\]) * Each patient must be aware of the nature of their disease and must willingly consent to treatment after being informed of alternatives, potential benefits, side effects, and risks * Surgery is done prior to IMT if needed for palliation, tumor debulking, pathological documentation of tumor recurrence; the patients may continue on study therapy even if they do not have measurable disease * No other investigational agents, immunomodulating agents, or cancer chemotherapy are permitted for the duration and 12 months following the study IMT unless there is disease progression; radiotherapy is not permitted; appropriate antibiotics, blood products, antiemetics, fluids, electrolytes and general supportive care are to be used as necessary Exclusion Criteria: * Resective surgery within 2 months prior to the initial pre-treatment AMT-PET scan * Severe increased intracranial pressure, status epilepticus, or other serious complications from the brain tumor, requiring emergency or urgent intervention * Patients with a history of another malignancy within 5 years of study enrollment * Patients with extracranial metastases * Evidence of active bleeding or bleeding diathesis * Patients will be ineligible for treatment on this protocol if (prior to protocol entry): * There is a history of a recent (within one year) myocardial infarction * There is a current or prior history of angina/coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF \< 45% by MUGA or ECHO) * There is clinical evidence of congestive heart failure requiring medical management (irrespective of MUGA or ECHO results)